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PKCb-null (Prkcb/) mice are severely immunodefi-
cient. Here we show that mice whose B cells lack
PKCb failed to form germinal centers and plasma
cells, which undermined affinity maturation and anti-
body production in response to immunization. More-
over, these mice failed to develop plasma cells in
response to viral infection. At the cellular level, we
have shown that Prkcb/ B cells exhibited defective
antigen polarization and mTORC1 signaling. While
altered antigen polarization impaired antigen presen-
tation and likely restricted the potential of GC devel-
opment, defective mTORC1 signaling impaired
metabolic reprogramming, mitochondrial remodel-
ing, and heme biosynthesis in these cells, which
altogether overwhelmingly opposed plasma cell dif-
ferentiation. Taken together, our study revealsmech-
anistic insights into the function of PKCb as a key
regulator of B cell polarity and metabolic reprogram-
ming that instructs B cell fate.
INTRODUCTION
B cells are key components of adaptive immunity that provide
systemic defense against pathogenic infections through the pro-
duction of highly specific antibodies. Antibody-secreting plasma
cell generation depends on B cell activation, in which naive
B cells are instructed to undergo cycles of proliferation and dif-
ferentiation. The first signal required for B cell activation is initi-
ated upon specific engagement of the B cell receptor (BCR)1144 Immunity 48, 1144–1159, June 19, 2018 ª 2018 The Author(s).
This is an open access article under the CC BY license (http://creativeby its cognate antigen (Ag), resulting in a complex signaling
cascade and uptake of the BCR:Ag complex. The internalized
antigen is presented as cell surface peptides on class II major
histocompatibility complex molecules (MHC-II) (Batista and Har-
wood, 2009), resulting in the engagement of specific CD4+
helper T cells and thus providing a second signal for maximal
B cell activation. In vivo, activated B cells can rapidly differentiate
to antibody-secreting plasma cells or enter into germinal centers
(GCs) where BCR affinity maturation and class switch recombi-
nation take place (Rajewsky, 1996; McHeyzer-Williams and
McHeyzer-Williams, 2005; De Silva and Klein, 2015; Victora
and Nussenzweig, 2012). B cells in the GC shuttle between the
light and the dark zone and BCRs with high antigen affinity are
iteratively selected. These B cells exit the GC and differentiate
into either high-affinity antibody secreting long-lived plasma
cells or temporarily quiescent memory cells that can undergo
plasma cell differentiation upon re-encountering the same anti-
gen (McHeyzer-Williams and McHeyzer-Williams, 2005).
Previous efforts have established transcriptomic signatures
that distinguish the changes of identity to predict B cell fate de-
cision. For example, the high expression of the transcription fac-
tors BLIMP-1 (Prdm1) (Nutt et al., 2015; Shapiro-Shelef et al.,
2003) and IRF4 (Klein et al., 2006; Sciammas et al., 2006) are reli-
able hallmarks of plasma cells (effector) development, while the
expression of the transcription repressor BACH2 (Kometani
et al., 2013; Shinnakasu et al., 2016) can predict memory pro-
gression. However, the signaling network and regulatory mech-
anisms required for B cell fate decisions are not fully understood.
Recent data suggest that metabolic reprogramming during
lymphocyte activation is, in part, important for regulating fate de-
cisions in T cells (Pollizzi et al., 2016; Verbist et al., 2016; Yang
et al., 2013).
Protein kinase Cs (PKCs) are signaling molecules that play key
roles in many cellular processes. The PKC family is broadlyPublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. PKCb Promotes Robust B Cell Response In Vivo
(A) Splenic GC B cell populations (B220+NP+GL7+CD95+) as analyzed by flow cytometry 13 days after NP-KLH and alum immunization of WT or Prkcb/
chimeras.
(B) Confocal (203 objectives) tile images of the spleen of immunizedWT and Prkcb/mice showing B220 and GL7 staining. Scale bar, 700 mm. The quantity and
area of GCs were quantified using Imaris.
(C) Splenic Tfh cells (CD4+PD1+CXCR5+) were quantified 13 days after immunization.
(D) NP-specific IgG and IgM titers on the specified days were determined by ELISA.
(E) Splenic plasma cells (CD138+IgD) were quantified 13 days after immunization.
(F) Confocal (203 objectives) tile images of the spleen of immunizedWT and Prkcb/mice showing surface B220 and intracellular k staining. Scale bar, 700 mm.
The amount of intracellular-k+ cells were quantified using Imaris.
(legend continued on next page)
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divided into three subgroups: classical, novel, and atypical PKCs
(Mellor and Parker, 1998). These subgroups differ in both protein
sequences and mechanistic requirements for catalytic activity.
The classical PKCs require cytosolic calcium (Ca2+) for their ac-
tivity, while the novel and atypical PKCs do not (Mellor and
Parker, 1998). In B cells, PKCb is the most highly expressed
PKC member and plays a central part in propagating NF-kB
signaling and cell proliferation downstream of the BCR (Saijo
et al., 2002; Su et al., 2002). PKCb-null mice exhibit impaired
B cell development in the peritoneal cavity (Leitges et al., 1996)
and (more mildly) the spleen (Leitges et al., 1996) and diminished
humoral responses against T cell-dependent antigen (Leitges
et al., 1996).
Here we reveal that PKCb is essential for the regulation of an-
tigen polarization and cell-fate decision in activated B cells. Us-
ing mice whose B cells lack PKCb, we show that this protein is
essential for GCs and plasma cell development upon immuniza-
tion. Indeed, PKCb-deficient B cells exhibit impaired antigen
polarization and presentation that is likely to hinder GC develop-
ment. Additionally, PKCb promotes mTORC1-dependent mito-
chondrial remodeling and heme biosynthesis, resulting in
BLIMP1-driven plasma cell differentiation (Watanabe-Matsui
et al., 2011). Thus, our study provides mechanistic insights into
the key role of PKCb on B cell-fate decisions.
RESULTS
PKCb Promotes Germinal Center Formation and Plasma
Cell Differentiation
While Prkcb/ mice exhibit severe immunodeficiency in
response to T cell-dependent antigens (Leitges et al., 1996), it
is unclear whether B cells contribute to the severe phenotype
in these mice. To investigate whether the loss of PKCb in B cells
attenuates immune response in vivo, we initially generatedmixed
bone marrow (BM) chimeras whereby irradiated mMT mice
(mature B cell-deficient) were reconstituted with a mixture of
80% mMT BM and either 20% WT (WT chimeras) or 20%
Prkcb/ (Prkcb/ chimeras) BM. Thus, reconstituted Prkcb/
chimeras would harbor Prkcb/ B cells in an environment of
mostly WT cells. The degree of reconstitution was assessed 6
to 8 weeks after adoptive transfer (Figure S1A). We then chal-
lenged WT and Prkcb/ chimeras with NP23 conjugated to
keyhole limpet haemocyanin (KLH) and Alum via intra-peritoneal
injection and analyzed the immune response in the spleen at
day 13 (Figures 1A–1G). In WT chimeras, we observed robust
GC B cell development, indicated by the increased
B220+GL7+CD95+ population (Figure 1A). In contrast, we saw
a severe reduction in the GC B cell population in Prkcb/ chi-
meras (Figure 1A). By inspecting splenic sections using confocal
microscopy, we observed that both the quantity and area of GC
significantly decreased in immunized Prkcb/ chimeras (Fig-
ures 1B). Our data suggest that PKCb in B cells plays an impor-
tant role in promoting GC reaction.(G) NP-specific IgG- and IgM-secreting cells 13 days after immunization were qu
(H) Plasma cells (CD138+IgD) in the PLN of WT or Prkcb/ chimeras were qua
(I) PLN VACV-specific IgM-secreting cells 7 days after infection were quantified us
Each dot represents one mouse.
Error bars represent SEM. See also Figure S1.
1146 Immunity 48, 1144–1159, June 19, 2018We asked whether this was an intrinsic feature in Prkcb/
B cells and so we tested the ability of Prkcb/ B cells to differ-
entiate to GC-like B cells in vitro. We cultured primary WT and
Prkcb/ B cells with 40LB cells (Nojima et al., 2011) for 4 days
and measured GL7 and CD95 expression using flow cytometry.
We detected more than 80% of WT and Prkcb/ B cells exhib-
iting GC-like features by day 4 (Figure S1B), suggesting that
Prkcb/ B cells were capable of forming GC B cells.
The formation of GCs in vivo depends on follicular T helper
(Tfh) cells, as they provide essential co-stimulatory signals to
B cells (Vinuesa and Cyster, 2011). We therefore compared the
development of Tfh cells in WT and Prkcb/ chimeras 13 days
after immunization. We detected a robust induction of Tfh cells
(CD4+CXCR5+PD1+) in WT chimeras (Figure 1C). In contrast,
Tfh cell development in immunized Prkcb/ chimeras was
reduced compared to immunized WT chimeras (Figure 1C), indi-
cating that the absence of PKCb in B cells affected the develop-
ment of Tfh cells.
Robust GC reaction facilitates the production of class-
switched antibodies and affinity maturation. In line with a defec-
tive GC response (Figures 1A and 1B), Prkcb/ chimeras
showed delayed and diminished appearance of NP23-specific
IgG titer as compared to WT chimeras (Figures 1D and S1C),
suggesting that the production of class-switched antibodies
was affected by the loss of PKCb. Moreover, we found that the
IgG derived from Prkcb/ chimeras bound poorly to NP3 (Fig-
ure 1D), reflecting a lack of high-affinity IgG in immunized
Prkcb/ chimeras. These data demonstrate that antibody
class-switching and affinity maturation was affected in immu-
nized Prkcb/ chimeras.
Notably, we found that IgM production was completely abro-
gated in immunized Prkcb/ chimeras (Figure 1D). As primary
IgM titer is typically derived from extrafollicular plasma cells,
which are independent of the GC, we asked whether plasma
cell development was affected in the absence of PKCb. We
analyzed plasma cell differentiation in immunized WT and
Prkcb/ chimeras, and found that while WT chimeras exhibited
a 5-fold increase of splenic plasma cells (CD138+IgD) after im-
munization, no induction of plasma cell differentiation could be
detected in the Prkcb/ chimeras (Figure 1E). When inspecting
splenic sections by confocal microscopy, we observed amarked
reduction of plasma cells in the splenic extrafollicular area in
Prkcb/ chimeras versus WT chimeras (Figure 1F). These re-
sults were confirmed by ELISPOT analysis (Figure 1G). Taken
together, our findings suggest that PKCb plays an important
role not only in promoting GC response but also in the generation
of extrafollicular plasma cells.
To determine whether the loss of PKCb in B cells would also
affect plasma cell differentiation in the context of viral infection,
we challenged WT and Prkcb/ chimeras, intra-footpad, with
104 PFUof vaccinia virus and analyzed plasma cell differentiation
in the draining popliteal lymph nodes (PLNs) 7 days after infec-
tion. We observed robust CD138+IgD plasma cells formationantified by ELISPOT.
ntified 7 days after vaccinia infection using flow cytometry.
ing ELISPOT. All data are representative of at least 2 independent experiments.
in the PLNs of WT chimeras; in contrast, the development of
these cells was reduced in the PLNs of infected Prkcb/ chi-
meras (Figure 1H). Furthermore, ELISPOT analysis also revealed
a reduction in the amount of VACV-specific IgM-secreting cells
in the PLNs of infected Prkcb/ chimeras compared to WT chi-
meras (Figure 1I). Together, these results suggest an important
role for PKCb in plasma cell differentiation in vivo.
Antigen Polarization in B Cells Requires PKCb
Subsequently, we questioned how the loss of PKCb affects B cell
functions at the cellular level. BCR engagement results in a rapid
internalization of the BCR:Ag complex and the polarization of an-
tigen-containing compartments (Figure S2A), which was sug-
gested to be dependent on classical PKCs (Siemasko et al.,
1998). We therefore asked whether PKCb is specifically required
for antigen polarization in B cells. We stimulated primary WT,
Prkca/, and Prkcb/ B cells for 30 min with Alexa647-conju-
gated anti-IgM and compared antigen polarization using
confocal microscopy (Figures 2A and 2B). While about 60% of
WT B cells and 50% of Prkca/ B cells displayed polarized an-
tigen (Figures 2A and 2B), it was reduced to 30% in Prkcb/
B cells (Figure 2B). This result indicates that PKCb is required
for intracellular antigen polarization but not antigen internaliza-
tion (see STAR Methods; Figure S2B).
Antigen polarization is thought to facilitate efficient antigen
transfer to MHC-II molecules, required for the subsequent
presentation to T cells (Siemasko et al., 1998); therefore, we
examined whether Prkcb/ B cells were less capable of antigen
presentation (see STAR Methods). Accordingly, we stimulated
primary WT, Prkca/, and Prkcb/ B cells with anti-IgM and
Ea peptide-coated microspheres. The internalized Ea peptide
is transferred to MHC-II (I-Ab) and presented on the cell surface
(Rudensky et al., 1991), which we detected using an anti-MHC-
II:Ea antibody (Figure 2C). In WT and Prkca/ B cells, we
observed robust Ea-presentation corresponding to a 3-fold in-
crease inmean fluorescence intensity (MFI) by the end time point
(Figures 2C and 2D). However, theMFI was decreased by 50% in
Prkcb/B cells (Figures 2C and 2D), indicating that antigen pre-
sentation was impaired in Prkcb/ but not Prkca/ B cells. To
assess how this might influence presentation to T cells, we as-
sayed the response of WT and Prkcb/ B cells in co-culture
with OT-II CD4+ T cells (see STAR Methods). CellTrace Violet
(CTV)-labeled WT and Prkcb/ B cells were stimulated with
anti-IgM and OVA-coated microspheres and co-cultured with
CFSE-labeled OT-II T cells. After 3 days, we assessed the prolif-
eration of B and T cells using flow cytometry. WT and Prkcb/
B cells triggered comparable T cell proliferation; however, co-
cultured Prkcb/ B cells exhibited reduced proliferation
compared to WT B cells (Figures 2E and 2F) despite having
normal survival responses (Figures 2G and 2H). When Prkcb/
B cells received CD40L, anti-IgM, and IL-4 (potent stimuli that
mimicked B-T cell co-culture), they proliferated as robustly as
WT cells (Figure 2I), indicating that the impaired proliferation of
co-cultured Prkcb/ B cells was likely a result of reduced
T cell help. While Prkcb/ B cells induced the proliferation of
OT-II T cells (Li et al., 2001), the impaired antigen polarization
in Prkcb/ B cells correlated with a reduction in antigen presen-
tation to T cells. To further affirm this, we analyzed the effects of
nocodazole or Gö6976 (classical PKC inhibitor) on WT B cells.Treatment with either nocodazole or Gö8976 effectively blocked
antigen polarization (Figures S2C and S2D) and Ea presentation
(Figures S2E and S2F) compared to control. These findings
demonstrate that the altered polarization of antigen-containing
compartments impaired antigen presentation in Prkcb/
B cells.
Antigen polarization is necessary to coordinate synergistic
BCR and toll-like receptor 9 (TLR9) signaling in B cells (Chatur-
vedi et al., 2008; Eckl-Dorna and Batista, 2009). To test whether
synergistic signaling was affected in Prkcb/ B cells, CTV-
labeled WT, Prkca/, and Prkcb/ B cells were cultured with
anti-IgM and CpG-coated microspheres (see STAR Methods)
and IL-4. We observed robust proliferation in both WT and
Prkca/ B cells after 3 days of stimulation, while Prkcb/
Bcells failed to proliferate to the same extent (Figure 2J). This dif-
ference was ablated when we stimulated Prkcb/ B cells under
conditions where antigen polarization is irrelevant, such as with
unlinked CpG and anti-IgM (with IL-4) (Figure 2K; Chaturvedi
et al., 2008). This suggests that synergistic signaling in Prkcb/
B cells was attenuated due to the lack of antigen polarization. In
line with this, Prkcb/ B cells exhibited impaired PI3K signaling
when stimulated with microspheres, but not unlinked CpG and
anti-IgM (Figures S2G and S2H). Taken together, our data sug-
gest that PKCb is required for antigen polarization and presenta-
tion, which provides an explanation, at least in part, for the
reduction in Tfh and GC B cells in Prkcb/ chimeras.
PKCb Instructs Plasma Cell Differentiation in B Cells
Although the role of PKCb in antigen polarization likely contrib-
utes to the immunodeficiency in Prkcb/ chimeras, the abroga-
tion of plasma cell differentiation in Prkcb/ chimeras made us
wonder whether PKCb plays other roles in B cell differentiation.
To test this, we analyzed plasma cell differentiation of WT and
Prkcb/ B cells cultured in vitro with CpG, anti-IgM, IL-4, and
IL-5 using flow cytometry. We found that plasma cell differentia-
tion was reduced by more than 60% in stimulated Prkcb/
B cells compared to those of the WT, while class-switch recom-
bination (as measured by expression of IgG1) was unaffected
(Figure 3A). We observed similar trends when Prkcb/ B cells
were cultured in CD40L (Figure 3B), LPS (Figure 3C), or with
40LB cells (Figures S3A and S3B), suggesting that this was inde-
pendent of specific exogenous signals. Furthermore, we found
that more Prkcb/ cells underwent class switching compared
to the WT in response to LPS and 40LB stimulation (Figures
3C, S3A, and S3B). Notably, these changes in differentiation
did not correlate to cell proliferation (Figures S3C and S3D), sug-
gesting that this might be a misstep in fate decision. Taken
together, our data demonstrate that PKCb plays an intrinsic
and crucial part in promoting plasma cell differentiation in B cells.
The initiation of the plasma cell differentiation requires the
dual-regulation of transcription factors, PAX5 and IRF4 (Nutt
et al., 2015). To understand how PKCb regulates plasma cell
development, we analyzed IRF4 and PAX5 expression in LPS-
stimulated (with IL-4 and IL-5) WT and Prkcb/ B cells by flow
cytometry (Figures 3D and 3E). We found that PAX5 and IRF4
expression increased in WT B cells on day 1 and 2 of the assay.
On day 3, IRF4hi cells downregulated PAX5 and adopted the
typical plasma cell (IRF4hiPAX5lo) signature, with a doubling of
this population detected by day 4 (Figures 3D and 3E). WeImmunity 48, 1144–1159, June 19, 2018 1147
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Figure 2. PKCb Facilitates Intracellular Antigen Trafficking in B Cells
(A) Confocal images (633 objectives) of primary WT, Prkca/, and Prkcb/ B cells stimulated with Alexa647-conjugated anti-IgM for 30 min. Magenta dots
indicate the corresponding MTOC. Bars, 5 mm.
(B) The extent of antigen polarization was quantified using ImageJ. Data were analyzed using two-way ANOVA.
(C) Representative plots of surfaceMHC-II:Ea expression as detected by anti-MHC-II:Ea antibody. Data are representative of at least 2 independent experiments.
(D) MFI of MHC-II:Ea was quantified. Data were analyzed using two-way ANOVA and are representative of 3 independent experiments.
(E) Primary WT and Prkcb/ B cells incubated with anti-IgM and OVA-coated beads and co-cultured with OT-II T cells. Representative plots showing CFSE and
CTV dilutions on day 3. Data are representative of at least 2 independent experiments.
(F) Quantification of CTV-divisions of WT and Prkcb/ B cells in the co-culture experiment.
(G and H) Representative plots and quantification of cell recovery of WT and Prkcb/ B cells after 3 days of co-culture.
(I) Representative plots of CTV dilutions of WT and Prkcb/ B cells stimulated with CD40L, anti-IgM, and IL-4 for 3 days.
(J and K) Representative plots of CTV dilutions of WT, Prkca/, and Prkcb/ B cells stimulated with (J) anti-IgM and CpG-coated microspheres with IL-4 and
IL-5, or (K) anti-IgM, CpG, IL-4, and IL-5 for 3 days. Data are representative of at least 2 independent experiments.
Error bars represent SEM. See also Figure S2.
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Figure 3. Prkcb–/– B Cells Fail to Commit to Plasma Cell Differentiation
(A–C) Representative plots and the corresponding quantifications of plasma cells and IgG1+ cells of WT and Prkcb/ B cells cultured in the presence of (A) CpG
and anti-IgM, (B) CD40L, and (C) LPS (all in the presence of IL-4 and IL-5) for 4 days. Data are representative of at least 2 independent experiments with 2 mice in
each group.
(legend continued on next page)
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discerned few differences in IRF4 and PAX5 expression in acti-
vated Prkcb/ B cells in the first 2 days of the assay; however,
on day 3 and 4, despitemaintaining an intermediate IRF4 expres-
sion, Prkcb/ B cells did not acquire the IRF4hiPAX5lo signature
(Figures 3D and 3E). Similar trends were observed using other
combinations of stimuli (Figure S3E). Thus, these results reveal
that Prkcb/ B cells fail to surpass the IRF4 expression
threshold that is required for plasma cell differentiation (Klein
et al., 2006; Sciammas et al., 2006).
To elaborate on these findings, we performed genome-wide
RNA sequencing (RNA-seq) on RNA extracted from WT and
Prkcb/ cells cultured with LPS, IL-4, and IL-5 for 2 days (see
STAR Methods) (Figures S4A–S4C; Table S1). Consistent with
the initiation of plasma cell differentiation (Nutt et al., 2015), we
observed upregulation (UP, log2 fold change > 0) of Prdm1 and
Irf4 and downregulation (DN, log2 fold change < 0) of Bach2,
Pax5, and Bcl6 in activated WT B cells compared to control cells
(IL-4 stimulated) (Figures 3F and S4A). When we compared acti-
vated Prkcb/ B cells with activated WT B cells (Figures S4B
and S4C), we found that in contrast to WT cells, Prkcb/ cells
exhibited decreased Prdm1, Irf4, and Ighm (m chain) expression
(Figure 3G) and increased Bcl6 and Pax5 expression (Figure 3G).
In line with unimpaired class switch recombination (Figures 3A–
3C, S3A, and S3B), Aicda, Bach2, and Ighg1 (g1 chain) expres-
sion were normal in Prkcb/ cells (Figure 3G; Muramatsu
et al., 2000; Muto et al., 2004). Taken together, our data suggest
that PKCb promotes the transcriptomic program necessary for
plasma cell differentiation.
PKCb Facilitates Metabolic Reprogramming and
Mitochondrial Remodeling in Activated B Cells
In order to understand how PKCb instructs the plasma cell differ-
entiation program, we applied gene set enrichment analysis
(GSEA) to identify gross transcriptomic changes in activated
Prkcb/ B cells. Within the 58 most downregulated (FDR %
0.001) gene sets in Prkcb/ B cells, we noticed a predominant
presence of gene sets relating to metabolism (Figure 4A).
GSEA also identified gene sets relating to endoplasmic reticulum
(ER) stress, protein modification, and anterograde membrane
trafficking (Figure S4D), which are expected events preceding
plasma cell differentiation. Specifically, expression of multiple
mitochondrial-related genes such as Atad1, Gpt2, and Hacd3
increased by 1.5-fold (log2 fold change R 0.5) after activation
in WT cells but not in Prkcb/ B cells (Figure 4B). Furthermore,
mirroring the GSEA results, the expression of several well-char-
acterized nutrient carriers such as Slc2a1 (GLUT1) and Slc3a2
(CD98) were also reduced in activated Prkcb/ B cells (Fig-
ure 4C; Table S1).
To examine the metabolic fitness of these cells, we compared
the metabolomic fingerprints of cultured WT and Prkcb/
B cells (see STAR Methods). Notably, we observed reduced
lactate abundance in the culture medium of Prkcb/ cells
compared to WT cells (Figure 4D). Next, we compared mito-(D) Expressions of PAX5 and IRF4 in primary WT and Prkcb/ B cells cultured i
(E) The size of IRF4hi cells (gated) was quantified. Data are of at least 2 independ
(F and G) MA plot of genes that are differentially expressed (red) with p-adj < 0.05
WT cells.
Error bars represent SEM. See also Figure S3.
1150 Immunity 48, 1144–1159, June 19, 2018chondrial oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR, which reflects lactate production) in
resting and activated WT and Prkcb/ B cells using the extra-
cellular flux (XF) system (Figures S5A–S5C). Accordingly, while
Prkcb/ B cells showed normal respiration under resting condi-
tions, in line with their metabolomics fingerprints, they exhibited
reduced basal OCR and ECAR after 1 day of culture in LPS
compared to WT cells (Figures S5A–S5C). Comparable OCRs
and ECAR were observed by day 2 (Figure S5C). These results
were corroborated by 13C-glucose labeling metabolomics on
activatedWT and Prkcb/B cells (see STARMethods), wherein
activated Prkcb/ B cells showed decreased labeling in lactate
and alanine and increased labeling in late TCA metabolites,
compared to WT cells (Figure 4E). Collectively, these results
suggest that PKCb promotes metabolic reprogramming during
B cell activation.
Given that the observed transcriptomic and metabolic
changes likely involve the mitochondria, we investigated the
mitochondrial status inWT andPrkcb/B cells before and after
stimulation with LPS, IL-4, and IL-5. To this end, we combined
MitoTracker green and MitoTracker red CMXROS staining to
monitor fluctuations in mitochondrial mass and mitochondrial
membrane potential (MMP) using flow cytometry (Figures
4F–4J). In WT B cells, LPS stimulation induced a rapid increase
of mitochondrial mass and MMP, followed by a gradual
decrease until the end of the assay on day 4 (Figures 4F
and 4G). In contrast, while exhibiting normal mitochondrial
mass and MMP at resting condition (Figures 4F and 4G),
Prkcb/ B cells showed increased accumulation of mitochon-
drial mass and MMP compared to WT cells on day 1 and 2 after
activation (Figures 4F and 4G). Furthermore, most of the
Prkcb/ B cells failed to downregulate mitochondrial mass
and MMP toward the end of the assay (Figures 4F–4I), in agree-
ment with lack of plasma cell differentiation (Jang et al., 2015;
Martı́nez-Martı́n et al., 2017). Likewise, the ratio between mito-
chondrial mass and MMP, which is indicative of mitochondrial
quality, was reduced in activated Prkcb/ B cells (Figure 4J),
indicating that mitochondrial homeostasis was altered in acti-
vated Prkcb/ B cells.
Mitochondria influence B cell fate via mROS generation (Jang
et al., 2015). Importantly, while we observed similar mROS accu-
mulation in resting WT and Prkcb/ B cells, mROS accumula-
tion was increased in Prkcb/ B cells immediately following
activation (since day 1) compared to WT B cells (Figure 4K),
temporally coinciding with the relative mitochondrial quality (Fig-
ure 4J). UnlikeWT cells, the addition of ascorbic acid (ROS scav-
enger) did not increase plasma cell differentiation in Prkcb/
B cells (Figures S5D–S5F; Jang et al., 2015). Likewise, other
mitochondrial-targeting antioxidants mitoquinone (MitoQ) and
MitoTempo were ineffective in this context (Figures S5G and
S5H), indicating that although high mROS might have
suppressed plasma cell differentiation in Prkcb/ B cells, low
mROS alone was not sufficient to promote plasma celln LPS, IL-4, and IL-5 for 4 days.
ent experiments with 2 mice in each group.
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Figure 4. Activated Prkcb–/– B Cells Exhibited Abnormal Metabolism and mROS Accumulation
(A) GSEA plots of selected downregulated gene sets in Prkcb/ B cells.
(B and C) Hierarchical clustered heatmaps showing expression of genes relating to (B) mitochondria and (C) solute carriers (Slc).
(legend continued on next page)
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Figure 5. Heme Addition Restores Effector
Differentiation in Prkcb–/– B Cells
(A) MA plot showing downregulation of Hmox1 in
Prkcb/ B cells.
(B) The relative accumulation of PpIX as quantified
by flow cytometry in WT and Prkcb/ B cells
cultured in LPS, IL-4, and IL-5.
(C and D) mROS, PAX5, and IRF4 expression,
CD138+ and IgG1+ cells as quantified by flow cy-
tometry in WT and Prkcb/ B cells cultured in LPS,
IL-4, and IL-5 for 4 days in the absence or presence
of hemin (added on day 1). Data were analyzed
using two-way ANOVA and are representative of at
least 3 independent experiments.
Error bars represent SEM.differentiation in the absence of PKCb. Overall, our findings
demonstrate that PKCb is essential to promote the fitness of
mitochondrial and non-mitochondrial metabolism and regulate
mitochondrial status and mROS homeostasis.
Mitochondrial Metabolism Couples Heme Biosynthesis
to Drive Plasma Cell Differentiation
We next questioned how metabolism could affect plasma cell
differentiation. Plasma cell differentiation is associated with
increased biosynthesis of heme (Watanabe-Matsui et al., 2011;
Jang et al., 2015), a porphyrin that is capable of inhibiting the ac-
tivity of the transcription factor BACH2 (Watanabe-Matsui et al.,
2011). Heme biosynthesis is a metabolite-demanding multistep(D) The normalized abundance of polar metabolites in culture supernatant as determined using gas chrom
Prkcb/ B cells cultured in LPS, IL-4, and IL-5 for 2 days. Data are representative of 2 independent expe
(E) Percentage of 13C incorporation in activated WT and Prkcb/ B cells. Each dot represents one mouse
(F–K) MFIs of MitoTracker Green (F), MitoTracker Red CMXRos (G), two-dimension representation (H and
Prkcb/ B cells cultured in LPS, IL-4, and IL-5 for 4 days. Data are representative of 3 independent expe
Error bars represent SEM. See also Figures S4 and S5.
1152 Immunity 48, 1144–1159, June 19, 2018process (Ajioka et al., 2006) and is inhibited
by high mROS (Jang et al., 2015). Given
that Prkcb/ B cells exhibited altered
metabolism and mROS accumulation, we
tested whether heme biosynthesis was
impaired in Prkcb/ B cells. We found
that the expression of Hmox1 (hemoxyge-
nase-1), typically induced by heme accu-
mulation (Watanabe-Matsui et al., 2011),
was among the DN genes found in acti-
vated Prkcb/ B cells (Figure 5A). We
also observed that Protoporphyrin IX
(PpIX, the final substrate of heme biosyn-
thesis) accumulation was reduced in acti-
vated Prkcb/ B cells compared to WT
cells (Figure 5B), indicating that metabolic
changes in activated Prkcb/B cells likely
impaired heme biosynthesis and caused
BACH2 hyperactivity.
Thus, to test whether heme supplemen-
tation would reverse fate decision in acti-
vated Prkcb/ B cells, we cultured WT
and Prkcb/ B cells in LPS (with IL-4and IL-5) in the presence or absence of exogenous hemin. On
day 3 and 4, we analyzedmROS accumulation, IRF4 expression,
plasma cell differentiation, and class switch recombination using
flow cytometry (Figures 5C and 5D). Hemin addition reduced
mROS accumulation and restored IRF4 expression (Figure 5C)
and plasma cell differentiation (Figure 5D) in Prkcb/ B cells.
These changes corresponded with a reduction in class switch
recombination (Figure 5D), indicating a hemin-driven fate-deci-
sion switch (Jang et al., 2015; Watanabe-Matsui et al., 2011).
Thus, our data suggest that PKCb promotes an activation-
induced metabolic program necessary for mROS homeo-
stasis and heme biosynthesis that is critical for B cell fate
determination.atography-mass spectrometry (GC-MS) of WT and
riments of 2 mice in each group.
(n = 5) and is the average of 3 technical replicates.
I), their ratios (J), and MFI of MitoSOX (K) in WT and
riments.
PKCb Controls Mitochondrial Status and mROS
Accumulation Partly through mTORC1
The mTORC1 signaling pathway is known to play an important
role in cell growth, protein synthesis, and metabolism, as well
as the regulation of mitochondrial biogenesis and function
(Laplante and Sabatini, 2013; Morita et al., 2013). In order to
examine whether the metabolic changes observed in Prkcb/
B cells involved alterations in mTORC1 signaling, we compared
mTORC1 activity in WT and Prkcb/ cells before and after
stimulation (Figures 6A, 6B, and S6A). Using flow cytometry,
we noticed that a portion of WT B cells initiated mTORC1
signaling on day 1, characterized by ribosomal protein S6
phosphorylation (Figure 6A), cell blasting (Figure S6A), and sur-
face expression of CD98 and CD71 (Figure 6B; Yang et al.,
2013). This mTORC1-active population doubled by day 2 (Fig-
ures 6A, 6B, and S6A). In contrast, this population was reduced
in activated Prkcb/ B cells (Figures 6A, 6B, and S6A). Consis-
tently, we observed decreased GLUT1 expression and altered
expression of mTORC1-associated genes (Cunningham et al.,
2007; Laplante and Sabatini, 2013; Yang et al., 2013) in acti-
vated Prkcb/ B cells (Figures S6B and S6C). Importantly,
while the upregulation of mTORC1 activity was a general
feature of B cell activation (Figure S6D), high mTORC1
signaling and CD98 expression specifically correlated with
plasma cell differentiation (Figure S6D). Taken together, these
data provide evidence that PKCb is important for mTORC1
signaling during early B cell activation.
Given that defects in mTORC1 signaling temporally coincides
with alterations in metabolic reprogramming in Prkcb/ cells,
we questioned whether disruption of mTORC1 signaling in WT
B cells was sufficient to affect cell fate. Accordingly, we cultured
WT B cells in LPS (with IL-4 and IL-5) for 4 days and inhibited
mTORC1 function using rapamycin at different stages of B cell
activation. We analyzed mROS accumulation and plasma cell
differentiation on day 3 and day 4 using flow cytometry (Fig-
ure 6C). Notably, we found that inhibition of mTORC1 signaling
on day 1 enhanced mROS accumulation and reduced plasma
cell differentiation, which was in line with our observations in
Prkcb/ B cells (Figure 6C). In contrast, we noticed that
mTORC1 inhibition on either day 2 or 3 only mildly affected
mROS accumulation and plasma cell differentiation (Figure 6C),
suggesting that fate decision in B cells involves an early and
somewhat transient wave of mTORC1 activity, corroborating
recent findings (Ersching et al., 2017). Mechanistically, rapamy-
cin treatment suppressed mTORC1 activity (Figure 6D), reduced
cell size (Figure S6E), and decreased CD98 and CD71 expres-
sion (Figure 6E) and PpIX accumulation (Figure 6F), which was
reminiscent of Prkcb/ B cells. We thus questioned whether
the lack of plasma cell differentiation rapamycin-treatedWT cells
was a consequence of reduced heme accumulation as in
Prkcb/ cells. To address this, we measured plasma cell differ-
entiation of WT B cells in the presence of rapamycin alone or of
rapamycin and hemin (Figures 6G and 6H). We found that hemin
supplementation partially increased plasma cell differentiation in
rapamycin-treated cells without alleviating mTORC1 inhibition
(Figures 6G, 6H, and S6F), indicating that rapamycin inhibited
plasma cell differentiation via heme homeostasis. Taken
together, these results demonstrate that mTORC1 mediates
plasma cell differentiation through mROS and heme homeosta-sis, providing a mechanism of the defects observed in Prkcb/
B cells.
Early mTORC1 Activity Promotes and Sustains Effector
Fate Commitment in B Cells
We were intrigued by the observation that hemin seemed to be
more potent to Prkcb/ cells than rapamycin-treated WT cells.
To better understand the relationship between heme homeosta-
sis, mTORC1, and plasma cell differentiation, we studied the ef-
fect of hemin and rapamycin on BLIMP1 expression inWTB cells
using the Prdm1gfp system (Figures 7A–7C; Kallies et al., 2004).
We noticed that hemin not only induced BLIMP1 expression
(Watanabe-Matsui et al., 2011) but also increased S6 phosphor-
ylation, cell blasting, and CD98 expression (Figures 7A–7C).
Importantly, resting B cells did not respond to hemin (Fig-
ure S6G), suggesting that while hemin promoted mTORC1 activ-
ity in activated B cells, it alone could not initiate mTORC1
signaling or plasma cell differentiation. On the other hand, rapa-
mycin treatment not only inhibited mTORC1 activity, it also sup-
pressed BLIMP1 expression, cell blasting, and CD98 expression
(Figures 7A–7C). Collectively, our results strongly support a
model of plasma cell differentiation that involves the crosstalk
between mTORC1, BACH2, and BLIMP1 (Figure 7D).
To confirm that this was indeed the mechanism of rescue in
Prkcb/ B cells, we stimulated Prkcb/ B cells in vitro with or
without exogenous hemin andmeasured mTORC1 activity using
flow cytometry (Figure 7E). Consistent with our hypothesis, we
found that hemin addition increased S6 phosphorylation (Fig-
ure 7E) andCD98 expression (Figure 7E) inPrkcb/B cells, sug-
gesting that hemin restored plasma cell differentiation via the
indirect activation of mTORC1 in the absence of PKCb. Collec-
tively, our data had revealed a vital role of PKCb in B cell fate
decision through the initiation of the mTORC1-BACH2-BLIMP1
program.
We wanted to determine whether deregulation of the
mTORC1-BACH2-BLIMP1 program underlies the lack of plasma
cell differentiation in other systems that are known to have PI3K
or mTOR signaling deficiencies, such as CD19-deficient B cells
(Buhl et al., 1997; Keppler et al., 2015). We therefore cultured
WT and Cd19/ B cells in LPS (with IL-4 and IL-5) in the pres-
ence or absence of exogenous hemin (Figures 7F–7H). We found
that while WT B cells exhibited high mTORC1 signaling and
robust CD98 expression 2 days after culture (as shown previ-
ously), activated Cd19/ B cells exhibited decreased mTORC1
activity and CD98 expression (Figure 7F), similar to Prkcb/
B cells. Hemin supplementation led to increased CD98 expres-
sion (Figure 7G), increased IRF4 expression, plasma cell differ-
entiation, and decreased class switch recombination in
Cd19/ B cells (Figure 7H). Taken together, our study proposes
a model in which B cell metabolic reprogramming sustains the
mTORC1-BACH2-BLIMP1 program and in turn drives effector
differentiation in B cells.
DISCUSSION
We have uncovered the decisive role of PKCb in B cell physi-
ology: PKCbmediatesGC reaction and plasma cell development
in response to T cell-dependent antigen challenge in vivo. While
the immunodeficiency in Prkcb/ chimeras appears to be aImmunity 48, 1144–1159, June 19, 2018 1153
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Figure 6. Prkcb–/– B Cells Had Impaired Early mTORC1 Signaling in Response to Activation
(A and B) Phosphorylation of S6, CD98, and CD71 surface expression as analyzed by flow cytometry ofWT and Prkcb/B cells cultured in LPS, IL-4, and IL-5 for
2 days. Data are representative of at least 3 independent experiments.
(C) mROS accumulation and plasma cell differentiation as quantified by flow cytometry in WT B cells cultured in LPS, IL-4, and IL-5 for 4 days. Rapamycin was
added at various time points as specified.
(D and E) S6 phosphorylation and CD98 and CD71 surface expression as analyzed using flow cytometry in WT B cells cultured in LPS, IL-4, and IL-5 for 2 days in
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Error bars represent SEM. See also Figure S6.
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consequence of multiple B cell-intrinsic impairments, we reason
that the loss of antigen polarization and presentation specifically
contribute to GC defects. Indeed, previous study had revealed
such correlation in Cdc42-deficient B cells (Burbage et al.,
2015). Impaired antigen presentation leads to reduced T cell
help in vivo, which could delay GC formation and affinity matura-
tion, as observed in both Prkcb/ and Cdc42/ B cells. We
speculate that the defects in antigen positioning in Prkcb/
B cells likely affects antigen transfer to other secondary com-
partments such as TLR9+ vesicles (Chaturvedi et al., 2008),
which may explain the poor synergistic signaling and prolifera-
tive response in these cells when stimulated with microspheres
in vitro. At this stage, howPKCb control antigen positioning is un-
clear, although we suspect that PKCb regulates organelle traf-
ficking (Siemasko et al., 1998; Kermorgant et al., 2003).
In line with our in vivo observations, PKCb-null mice fail to elicit
antibody titer upon primary T cell-dependent immunization
(Leitges et al., 1996). However, this appears to be less severe
in the recall response (Leitges et al., 1996), implying that PKCb
deficiency may not affect memory generation during the primary
challenge. Consistent with this, activated Prkcb/ cells were
able to induce Aicda, Bach2, and Ighg1 expression (Klein
et al., 2006; Muramatsu et al., 2000; Muto et al., 2004), as well
as undergoing class-switch recombination in vitro, which
together support the notion that the development of class-switch
compartment should be normal, if not enhanced in Prkcb/ chi-
meras. Future works should address whether BCR signaling is
affected in PKCb-deficient memory B cells.
We have shown that the lack of an mTORC1-mediated meta-
bolic reprogramming in Prkcb/ B cells suppresses plasma cell
differentiation. While mTORC1 inhibition is known to delay
BACH2 downregulation and suppress plasma cells differentia-
tion (Kometani et al., 2013), hyperactivity of mTORC1 enhances
plasma cell differentiation (Benhamron et al., 2015). Here, we
have shown that early mTORC1 signaling instructs plasma cell
differentiation through the crosstalk to BACH2, BLIMP1, and
metabolic reprogramming. We demonstrate that mTORC1 inhi-
bition not only suppresses respiration (Cunningham et al.,
2007; Morita et al., 2013) but also elevates mROS during B cell
activation. We have revealed mROS accumulation and heme
homeostasis as mechanistic connections between mTORC1
signaling and plasma cell differentiation. We speculate that
heme accumulation constitutes an intrinsic part of metabolic re-
programming in WT B cells: PpIX accumulation increases
concurrently with that of two mTORC1 targets, CD71 and
Hmox1 (Cunningham et al., 2007; Yang et al., 2013). Heme ex-Figure 7. Early mTORC1 Signaling Plays a Decisive Role in Effector Fa
(A–C) GFP expression, p-S6 (A), cell blasting (B), and CD98 and CD71 surface ex
LPS, IL-4, and IL-5 for 2 days in the presence of rapamycin or hemin (added on
(D) A proposed model relating mTORC1, BACH2, and BLIMP1.
(E) p-S6, CD98, and CD71 expression as determined using flow cytometry ofPrkcb
of hemin (added on day 1). Data are representative of at least 2 independent exp
(F) S6 phosphorylation, CD98, and CD71 surface expression as measured by flo
(G) Quantification of CD98 surface expression in Cd19/ B cells cultured in LPS,
Data are representative of 2 independent experiments.
(H) Expressions of PAX5, IRF4, CD138, and IgG1 and the corresponding quantifica
IL-4, and IL-5 for 3 days in the absence or presence of hemin (added on day 1).
pendent experiments.
Error bars represent SEM.
1156 Immunity 48, 1144–1159, June 19, 2018hibits anti-oxidant properties through hemoxygenase-depen-
dent degradation (Ryter and Tyrrell, 2000), which could also be
relevant in this setting.
In terms of the mode of metabolic reprogramming, our results
provided further evidence that B cells increase glycolytic flux
upon activation (Garcia-Manteiga et al., 2011; Wang et al.,
2011) and that PKCb plays a role in regulating these changes
(Blair et al., 2012). Although respiratory rate might not directly
affect cell fate in B cells (Jang et al., 2015), metabolic status
can heavily influence other downstream pathways through the
supply of metabolites derived. In line with this, our metabolomics
results indicate that activated Prkcb/ B cells exhibit a shift to-
ward oxidative phosphorylation in compared to WT cells. While
this may be beneficial to activated Prkcb/ B cells to supple-
ment ATP production, it may divert metabolites from other
biosynthetic processes necessary for cell growth and differenti-
ation, such as succinyl-CoA that is required for heme biosyn-
thesis. Additionally, mitochondrial status may influence the
localization of heme biosynthetic enzymes. Thus, our results
reflect that changes inmitochondria during B cell activation likely
sustain the mTORC1-BACH2-BLIMP1 program through biosyn-
thesis of heme.
HowmTORC1 signaling is coupled to PKCb is not addressed in
this study. Inmammalian cells, mTORC1 signaling is regulated by
both PI3K-dependent and PI3K-independent mechanisms (Lap-
lante and Sabatini, 2013). Notably, mTORC1 activity can be
altered by nutrient availability, such as glucose or amino acids
(Donahue and Fruman, 2007). Nutrient availability also affects
lysosomepositioning,whichalso influencemTORC1activity (Kor-
olchuketal., 2011).Relianceoneachof these regulatorypathways
is context specific (Donahue and Fruman, 2007). Indeed, we
observed a strong correlation between the activity of mTORC1
and expression of CD98 inWTB cells, suggesting that the regula-
tion of mTORC1 may switch from PI3K dependent to PI3K inde-
pendent at some point during B cell activation. While the use of
fully supplemented media in our in vitro assays unlikely restricts
nutrient availability, mTORC1 activity may be affected by altered
surface expression of nutrient transporters such as GLUT1 or
CD98 in Prkcb/ B cells (Caro-Maldonado et al., 2014; Sinclair
et al., 2013). It is also possible that mTORC1 defects in Prkcb/
B cells are a result of lysosome misplacement (Korolchuk et al.,
2011; Siemasko et al., 1998). These would be in line with the role
of PKCb in vesicular trafficking described in this study and previ-
ously (Kermorgant et al., 2003). Moreover, the lack of Prdm1 in-
duction in Prkcb/ B cells can further suppress mTORC1
signaling through the lossof positive feedback (Tellier et al., 2016).te Decision in B Cells through Heme Metabolism
pression (C) as measured by flow cytometry of Prdm1+/GFP B cells cultured in
day 1).
/B cells cultured in LPS, IL-4, and IL-5 for 2 days in the absence or presence
eriments.
w cytometry of WT. Data are representative of 2 independent experiments.
IL-4, and IL-5 for 2 days in the absence or presence of hemin (added on day 1).
tions as analyzed by flow cytometry ofWT andCd19/Bcells cultured in LPS,
Data were analyzed using two-way ANOVA and are representative of 2 inde-
An increasing body of evidence suggests that mTORC1
signaling and metabolic reprogramming are key determinants
for lymphocyte fate decisions. In activated T cells, mTORC1
signaling cooperates with Myc to determine effector functions
(Pollizzi et al., 2016; Verbist et al., 2016). We speculate that
much of these also apply to B cells. Indeed, systems previously
reported to exhibit defective PI3K or mTORC1 signaling, such as
Cdc42/ and Wipf/, all display altered ‘‘effector’’ versus
‘‘memory’’ fate decisions (Burbage et al., 2015; Keppler et al.,
2015). With the inclusion of the Prkcb/ and Cd19/ model
presented in this study, there is a convincing body of evidence
that illustrates the decisiveness of mTORC1 signaling axis in
steering fate decision in B cells (Benhamron et al., 2015; Kome-
tani et al., 2013). Given that the dependence on mTORC1 seems
to be transient, we speculate that early mTORC1 activity may
initiate a crosstalk with BACH2, BLIMP1, and metabolic reprog-
ramming, which later becomes a self-propagating program via
positive feedback mechanisms to promote plasma cell differen-
tiation. This would be in line with the behavior and function of
mTORC1 activity in GC B cells (Ersching et al., 2017). Finally,
we have identified the crucial role of PKCb in promoting early
mTORC1 signaling and regulating transcriptomic and metabolic
reprogramming, which together instruct and maintain effector
function in activated B cells.
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EXPERIMENTAL MODELS
Animal breeding and generation
PKCb-deficient and PKCa-deficient mice were kindly provided by Michael Leigtes, Oslo. All mice were bred and maintained at the
animal facility of Cancer Research UK and The Francis Crick Institute. The Animal Ethics Committee of Cancer Research UK, The
Francis Crick Institute and the UK Home Office approved all experiments.
Immunization, infection, ELISA and ELISPOT
For immunization, mice were injected intra-peritoneally with 50 mg NP23-KLH (Biosearch Technology) in 4 mg Alum
(ThermoScientific). Blood samples were taken from the lateral tail-vein on day 0, 3, 7, 13, 28 after immunization. For infection, 104
PFU of Vaccinia Virus Western Reserve strain (vacv) was injected into isoflurane-anesthetized animals in the footpads. NP-specific
antibody titers were detected by ELISA, using NP23-BSA, NP3-BSA, and biotinylated anti–mouse IgM and IgG (Southern Biotech).
Titers were determined from the dilution curve in the linear range of absorbance. All non-commercial ELISA plates were developed
with alkaline-phosphatase streptavidin (Sigma) and phosphorylated nitrophenyl-phosphate (Sigma). Absorbance at 405 nm was
determined with a SPECTRAmax190 plate reader (Molecular Devices). NP-specific antibody-secreting cells and vacv-specific anti-
body-secreting cells were captured using activated ELISPOT plates coatedwith either NP23-BSA or vacv respectively. Detectionwas
made using biotinylated anti–mouse IgM (Southern Biotech), IgG (Southern Biotech). All ELISPOT plates were developed with alka-
line-phosphatase streptavidin (Sigma) and the BCiP/NBT reaction (Sigma). Images were acquired using CTL 4.0 (ImmunoSpot).
Cell isolation, labeling and culture
Splenic naive B or CD4 T lymphocytes were purified using negative B cell or CD4 T cell isolation kits yielding enriched populations of
95%–98% (B cells) and 80% (T cells), respectively (Miltenyi Biotec). Purified B or T cells were labeled in PBS with 2 mM CTV
(Invitrogen) or 1 mM CFSE (Invitrogen) for 5 minutes at 37C with 5% CO2. Cells were maintained in complete B cell medium
(RPMI 1640 supplemented with 10% FCS, 25 mMHEPES, Glutamax, penicillin and streptomycin (Invitrogen), and 1% b-mercaptoe-
thanol (Sigma)). For iGC feeder (40LB) cells, cells were cultured in DMEM supplemented with 10% FCS and penicillin and strepto-
mycin (Invitrogen). Initial selection for CD40L- and BAFF-expressing cells was performed using G418 and puromycin as described
(Nojima et al., 2011).Immunity 48, 1144–1159.e1–e5, June 19, 2018 e2
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Proliferation analysis
CFSE- or CTV–labeled cells at a concentration of 106 cells per mL were stimulated in complete B cell medium supplemented with
combinations of 1 mg/mL LPS (Sigma) or 0.05 mg/ml CD40L (R&D Systems), 5 mg/ml anti-IgM F(ab)2 fragment (Jackson
ImmunoResearch), 1.5 ug/mL CpG (Sigma) 10 ng/ml of IL-4 (R&D Systems), or 10 ng/ml of IL-5 (R&D Systems). CFSE or CTV dilution
was measured after 3 or 4 days by flow cytometry. Various agents were added as follow: L-ascorbic acid (200 mM) on day1, Mito-
qunione of specified concentrations, MitoTempo of specified concentrations, hemin (60 mM) on day 1 and Rapamycin (50 nM) on the
specified time points.
Antigen internalization and presentation
For internalization assays, purified B cells were loaded with IgM-coated beads on ice for 60 minutes. Cells were then washed with
complete medium to remove excess antigen, and then incubated for 30minutes at 37C. Cells were fixed at different time points with
4% formaldehyde. After fixation, beads remaining on the cell surface were detected with Alexa488 streptavidin (eBioscience). To
detect antigen presentation, B cells loaded with Ea peptide and IgM-coated beads were incubated between 3 and 5 hours at
37C, and then fixed in 4% formaldehyde. These cells were then stained with anti-MHCII:Ea antibody, followed by anti–mouse
IgG2b antibody staining for detection by flow cytometry.
Microspheres preparation
For proliferation assay, 0.11 mm (diameter) streptavidin-coated microspheres (Bangs Laboratories) were incubated with a satu-
rating amount of biotinylated anti-IgM and biotinylated-CpG (Sigma) or OVA (EMD Millipore) for 1 hour at 37C, and washed to
removed unbound molecules. For presentation assays, 0.11 mm red microspheres (Bangs Laboratories) were incubated with a
saturating amount of biotinylated anti-IgM (Southern Biotech) and Ea peptide or OVA (EMD Millipore) for 1 hour at 37C. Limiting
stimulatory conditions were obtained by increasing the amounts of OVA or Ea peptide for coating, whereas IgM amounts were
kept constant. Efficient titration of the IgM signal was measured by flow cytometry. Beads coated with anti-IgM were used as
negative control. Red microspheres (Bangs Laboratories) coated with biotinylated anti-IgM (Southern Biotech) were used for inter-
nalization assay.
Ea Peptide
Biotin-GSGFAKFASFEAQGALANIAVDKA-COOH was produced by the Crick Peptide Chemistry facility.
Flow cytometry
For analysis of splenocyte populations, single-cell suspensions were prepared from homogenized spleens. Erythrocytes were de-
stroyed with Lysis Buffer (BD Biosciences). Cells were treated with the appropriate combination of the following antibodies:
CD16/32 (Fc block), B220, CD19, CD44, PD1, IgG1, IgD, CD95, GL7, CXCR5, CD4, and CD138. For analysis of in vitroB cell cultures,
after blocking Fc receptors using anti-CD16/32 antibodies, CTV-labeled cells were stained with the antibodies CD138, IgG1, CD98
and CD71. For intracellular detection of PAX5, IRF4, p-S6K1, p-S6 and GLUT1, after blocking Fc receptors using anti-CD16/32 an-
tibodies, cells were fixed and permeablized with Cytofix/Cytoperm (BD Biosciences). Antibody against PAX5 and IRF4 diluted in 1x
Perm/Wash (BDBiosciences) were used. Primary antibody against p-S6K1, p-S6, GLUT1 and secondary Alexa488 or Alexa555-con-
jugated Goat-anti-Rabbit IgG antibody (Life Technologies) was used for their detection. Mitochondrial status was measured using
MitoTracker Green (20 nM), MitoTracker Red CMXRos (20 nM) and MitoSOX (5 mM). Cells were labeled for 30 minutes at 37C. Cells
were washed once with 2% FCS supplemented PBS and analyzed by flow cytometry. The relative mitochondrial quality was calcu-
lated by normalizing the intensity (MFI) of MitoTracker Red CMXRos to the intensity (MFI) of MitoTracker Green. Data were acquired
on LSR Fortessa (BD) and analyzed with FlowJo (Tree Star).
PpIX measurement
Cells were analyzed using flow cytometry. Excitation at 405nm and emission at 605/40 nm were used.
Immunoblotting
Purified B cells were left at 37C for 10minutes in Imaging buffer (PBS, 0.5% FCS, 1 g/L D-Glucose, 2mMMgCl2, and 0.5 mMCaCl2)
to equilibrate before stimulation. They were then stimulated for various times with 5 mg/ml anti-IgM F(ab)2 fragment (Jackson
ImmunoResearch) and 1.5 ug/mL CpG, 10 ng/ml of IL4, 10 ng/ml of IL-5, or coated microspheres (see previous section). For immu-
noblotting, stimulated cells were then lysed in lysis buffer (20 mM Tris-HCL, pH 8.0, 150 mM NaCl, 5 mM EDTA, Protease Inhibitor
cocktail (Roche), 10 mM NaF, 1 mM Na3VO4, and 1% NP-40) for 30 minutes on ice, and samples were loaded into 12% PAGE gel
(BIO-RAD) for electrophoresis. Proteins were detected with antibodies against p-Akt (Ser473), p-S6k1 (Thr389) and Erk using the
secondary HRP-conjugated anti–rabbit or anti–mouse antibodies (see Key Resources Table). Blot densitometry analysis was
performed using the ImageJ (National Institutes of Health) software.e3 Immunity 48, 1144–1159.e1–e5, June 19, 2018
Optical microscopy
Spleens were embedded in OCT and frozen in cold isopentane and 10 mm-wide frozen sections were cut with a cryostat. Sections
were dehydrated and fixed in 4%paraformaldehyde, blockedwith PBS containing 1%BSA, and 10%goat serum (IF blocking buffer).
To label plasma cell population architecture, sections were also permeablized with PBS 0.3% Triton for 3 minutes. Staining was per-
formed in IF blocking buffer with a combination of the following antibodies: B220, anti-k, and GL7. Confocal imaging was performed
with a LSM 780 microscope (Carl Zeiss) with a plan apochromat 20 3 , NA 0.8 objective for tissue sections or a plan apochromat
633 , NA 1.40 objective for other applications. Images were analyzed with Imaris (Bitplane) or ImageJ software. For tissue sections,
tiled images were acquired and assembled with the Zen software.
RNA sequencing and bioinformatics analysis
RNA from B cells were extracted and purified with MagMAXTM RNA isolation kit (Life Technologies). Samples were processed with
KAPA hyper prep and sequenced using the HiSeq 4000 system. Sequencing on biological triplicates (WT) and duplicates (Prkcb/)
generated libraries ranging 40-70 million, 101 bp paired end reads. Read trimming and adaptor-removal were performed using Trim
Galore! (version 0.4.2). The RSEM package (version 1.2.31), and Bowtie2 (version 2.2.9) were used to align reads to the mouse
genome (Ensembl GRCm38 release 85) and to obtain gene level counts. For RSEM, all parameters were run as default except ‘–for-
ward-prob’ that was set to ‘0’. Differential expression analysis was carried out with DESeq2 package (version 1.14.1) within R version
3.3.2. Genes were considered to be differential expressed with padj% 0.05. Gene set enrichment Analysis (GSEA) (version 2.2.3) was
done for each pairwise comparison using gene lists ranked using the Wald statistic. Gene set pre-ranked analysis was carried out
with respect of gene sets C2 canonical pathways and C5 biological processes. All parameters were kept as default except for enrich-
ment statistic (classic) andmin/max size, whichwere changed to 5 and 50000 respectively. Gene signatureswith FDR q-value% 0.05
were considered significant. Heatmap of differential expressed genes belonging to gene ontologies; mitochondrion (GO:0005739)
were generated using the gplots CRAN package (version 3.0.1). Genes were clustered using an Eisen distance matrix and average
linkage clustering.
Metabolomics fingerprinting
Polar metabolites were extracted and analyzed by GC-MS as follows: 5 mL culture supernatant was removed from each sample and
polarmetabolites were phase-partitioned from apolarmetabolites by addition of 350 mL chloroform/methanol/water (1:3:3 v/v/v, con-
taining 1 nmol scyllo-inositol as internal standard). Centrifugation (13,000 rpm, 10mins, 4C) was used to separate phases. The polar
phase dried in a rotary vacuum concentrator and washed twice with methanol. Metabolites were analyzed as previously described
(MacRae et al., 2013). In brief, metabolites were derivatized bymethoximation [20 ml 20mg/ml methoxyamine-HCl (Sigma, 226904) in
pyridine (Sigma, 270970) at RT, overnight], and subsequent incubation with 20 ml N,O-bis(trimetylsilyl)trifluoroacetamide (BSTFA) +
1% trimethylchlorosilane (TMCS) (Sigma, 33148) forR 1 hr. Metabolite analysis was performed by GC-MS using an Agilent 7890B-
5977A system. Splitless injection (injection temperature 270C) onto a 30 m + 10 m 3 0.25 mm DB-5MS+DG column (Agilent J&W)
was used, with helium as the carrier gas, in electron impact ionization (EI) mode. The initial oven temperature was 70C (2 min), fol-
lowed by temperature gradients to 295Cat 12.5C/min and then to 320C25C/min (held for 3mins). Metabolites were identified and
quantified by comparison to the retention times, mass spectra, and responses of known amounts of authentic standards using
MassHunter Workstation software (B.06.00 SP01, Agilent Technologies).
Extracellular flux assay
Naive and activated B cells were resuspended in Seahorse medium supplemented with 11 mM glucose and 2 mM pyruvate with pH
adjusted to 7.4. Cells were settled on 96-well assay plate (Seahorse Bioscience) coated with poly-lysine (Sigma). OCR was recorded
with the XF96 Extracellular Flux analyzer. Oligomycin-sensitive OCR represents the difference in OCR before and after addition of
3 mM of Oligomycin A (Sigma). Other chemicals used: FCCP (5 mM) (Sigma); Rotenone (5 mM) (Sigma). Resting ECAR from the
same assay was plotted.
U-13C labeling assay
Bcells cultured for 2 dayswere labeledwith U-13C-glucose for 2 hours at 37C.Metabolic activity was quenched rapidly with ethanol/
dry ice slurry. Cells were lysed and metabolites were extracted as follows: 600 mL chloroform:methanol (3:1v/v) was added to each
sample and vortexed briefly before pulse sonication (33 8 minutes) in a water-bath sonicator at 4C for 1 hour. Samples were spun
(13,200 rpm, 4C, 10minutes), supernatant transferred to a new tube and dried in a rotary vacuum concentrator. The remaining pellet
was re-extracted with 600 mL methanol:water (3:1v/v) followed by pulse sonication for 8 minutes at 4C. Samples were spun
(as above), and the supernatant added to the first extract and dried. Extracts were suspended in 50 mL chloroform and 300 mL meth-
anol:water (1:1) to partition polar and apolar metabolites. Centrifugation (13,000 rpm, 10minutes, 4C) was used to separate phases.
150 mL of the polar phase were inserted in a LC-MS vial insert and 50 mL of a mixture of methanol/water (1:1 v/v, containing 1.5 nmol
13C, 15N-Valine as internal standard) were added. Metabolite analysis was performed by LC-MS using a Q-Exactive Plus (Orbitrap)
mass spectrometer from Thermo Fisher Scientific (Bremen, Germany) coupled with a Vanquish UHPLC system from Thermo Fisher
Scientific (Bremen, Germany). The chromatographic separation was performed on a SeQuant Zic-pHILIC (Merck Millipore)Immunity 48, 1144–1159.e1–e5, June 19, 2018 e4
column (5 mmparticle size, polymeric, 1503 4.6mm). The injection volumewas 10 mL, the oven temperature wasmaintained at 25C,
and the autosampler tray temperature was maintained at 4C. Chromatographic separation was achieved using a gradient program
at a constant flow rate of 300 ml/min over a total run time of 25 min. The elution gradient was programmed as decreasing percentage
of B from 80% to 5%during 17minutes, holding at 5%of B during 3minutes and finally re-equilibrating the column at 80%of B during
4minutes. Solvent Awas 20mMammonium carbonate and 1.4mL/L of a solution of ammonium hydroxide at 35% inwater (pH 9) and
solvent B was acetonitrile. Metabolites were identified and quantified by accurate mass and retention time and by comparison to the
retention times,mass spectra, and responses of known amounts of authentic standards using TraceFinder 4.1 EFS software (Thermo
Fisher Sientific). Label incorporation and abundance was estimated using TraceFinder 4.1 EFS software. The degree of labeling of
individual metabolites was estimated as the percentage of the metabolite pool containing one or more 13C atoms after correction for
natural abundance isotopes. Abundance was given relatively to the internal standard.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample sizes were chosen on the basis of published work in which similar phenotypical characterization and similar defects were
reported. Cohort randomization or ‘blinding’ of investigators to sample identity was not done in this study. For all statistical compar-
isons unless specified, the data for each groupwere comparedwith Student’s t test and P valueswere calculated. Normal distribution
of samples was assumed on the basis of published studies with analyses similar to ours. Statistically significant differences are indi-
cated on the figures as follows: *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005.e5 Immunity 48, 1144–1159.e1–e5, June 19, 2018
